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1. Introduction 
Models of the inflammatory process depict scenes of a drama that has being studied for 
millenniums. A drama that began at the macroscopic level, with Celsus and the aphoristic 
comment “Vero notae inflammationis sunt quatuor: rubor et tumor cum calore et dolore"1 ;  
with the four cardinal signs of inflammation, followed by Virchow at the microscopic  
level by proposing a response to insult model, and one that continues to unfold as we  
develop molecular representations of this process, in an attempt to complete the story of a  
drama. 
 
“If therefore we speak of an irritament2, we cannot properly intend to attach any other 
meaning to it, than that, in consequence of some cause or other external to the part which 
falls into a state of irritation, and acting upon it either directly or through the medium of 
the blood the composition and constitution of this part undergo alterations which at the 
same time alter its relations to the neighboring parts (whether they be blood-vessels or other 
structures) and enable it to attract to itself and absorb from them a larger quantity of matter 
than usual, and to transform it according to circumstances. Every form of inflammation 
with which we are acquainted, may be naturally explained in this way”. 
Rudolf Virchow 1858 
 
It’s an open secret, and we continue to publish it as if it is a surprise or new knowledge 
even. Whether we realize it or not we have evolved a new field; a field that is defined by the 
intersection of immunology and hemostasis. Platelets whose main purpose has traditionally 
been considered as a plug forming device, is currently participating in new paradigms of 
disease, as a sophisticated mediator in a milieu of chemokines and adhesion molecules 
which modulate the immune response and consequently inflammation. Studies from 
                                                 
1 “But the signs of inflammation are four; redness, and swelling, with heat & pain“ 
2 Inflammatory stimulus 
www.intechopen.com
Inflammation, Chronic Diseases and Cancer –  
Cell and Molecular Biology, Immunology and Clinical Bases 
 
98
inflammatory diseases such as sepsis, rheumatoid arthritis, and acute lung injury set the 
stage for modification of the thespian paradigm. One that helps us complete the continuum 
from coagulation to inflammation and back to coagulation again. Here we propose to name 
this field of study “Immunohemostasis”. No better model to appreciate the crosstalk 
between coagulation and inflammation than atherosclerosis. 
2. Platelets have a role early in the development of atherosclerosis 
Although platelets are not solely responsible for the development of atherosclerosis, their 
contribution to the inception of the vascular lesion, up until to atherothrombosis - its most 
critical consequence - is conceptually best understood as a model of inflammation. This is 
somewhat amusingly explained by Rudolf Virchow on a footnote in, Cellular Pathology 
(1865), “Suppose three people were sitting quietly on a bench, and suddenly a stone came 
and injured one of them, the others would be excited, not only by the sudden appearance of 
the stone, but also by the injury done to their companion, to whose help they would feel 
bound to hasten. Here the stone would be the irritant, the injury the irritament, the help an 
expression of the irritation called forth in the bystanders”. Following Dr. Virchow’s thought 
process, modern science not only has documented many different stones but also 
acknowledges that at times, these bystanders can hasten the irritament (inflammatory 
stimulus), therefore as we will understand an overzealous and excited bystander could 
prove to be, vessel hardening. 
If we look at atherosclerosis as a model of inflammatory disease, platelet adhesion could 
similarly be regarded as a model of platelet induced disease (Langer & Gawaz, 2008). 
Atherogenesis is influenced by platelets that adhere to activated vascular endothelial cells 
and feed chemotactic mediators to adjoining cells. Although the underlying mechanism of 
atherosclerosis is attributed to endothelial impairment due to insults from genetic and 
environmental factors (Lusis, 2000), it needs platelet firm adhesion to the endothelium for 
inception of the atheromatous plaque (Spagnoli et al., 2007). Genetic and environmental 
factors that trigger injurious events, which include the formation of reactive oxygen 
species, reduce the bioavailability of nitric oxide  (Lowenstein et al., 2005). Then the non-
denuded, but aggravated endothelium fails to inhibit control over Weibel–Palade body 
exocytosis translocating P-selectin  and von Willebrand Factor (vWF) from within the 
granules to the outer cellular surface (Wagner & Frenette, 2008). These two proteins allow 
the adhesion of platelets to the vascular endothelium in a multistep process. First platelets 
are tethered to the vascular wall with assistance by endothelial selectins. Platelets then 
roll on the vascular endothelial cells (Polgar et al., 2005). Depending on further activation 
of the endothelial cell and expression of endothelial integrins, the platelet adheres firmly 
to the vascular wall (May et al., 2008), or in the absence of further endothelial activation, 
the platelet, disengages from the vessel wall and returns to circulation (White, 2007). 
Remarkably this can occur due to the fact that platelet activation is not required for 
platelet rolling (Harrison, 2005). In contrast, experimental models of mice infused with 
activated platelets also stimulate Weibel–Palade body exocytosis, promoting the 
development of atherosclerosis which is attributed to platelet P-selectin – mediated 
delivery of platelet-derived proinflammatory factors to monocytes/leukocytes and the 
vessel wall (Delvaeye & Conway, 2009). 
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Molecule Tissue Distribution Function Ligand
Selectins 
P-selectin  Endothelium & platelets Rolling of leukocytes on 
endothelium and 
platelets & of platelets on 
endothelium
PSGL-1
E-selectin Endothelium Rolling of leukocytes on 
endothelium
PSGL-1 ESL-1 CD44 
Immunoglobulins 
ICAM-1 Endothelium Firm adhesion and 
transmigration of 
leukocytes
ǃ2-integrins 
ICAM-2 Endothelium, dendritic cells Firm adhesion &
transmigration of 
leukocytes; platelet 
adhesion to leukocytes 
ǃ2-integrins 
VCAM-1 Endothelium Firm adhesion &
transmigration of 
leukocytes
ǂ4-integrins 
PECAM-1 Leukocytes, endothelial cell-
cell junctions
Transmigration PECAM-1
Glycoprotein 
von Willebrand 
Factor 
Endothelium, ǂ-granules of 
platelets, & subendothelial 
connective tissue
Binding to other 
proteins, most efficient 
under high shear stress
Factor VIII, Collagen, 
Platelet GPIb 
 
Glycoprotein IV Platelets & monocytes Scavenger receptor, 
implicated in hemostasis, 
thrombosis, 
inflammation, lipid 
metabolism & 
atherogenesis
Collagen, 
thrombospondin, 
platelet-agglutinating 
protein p37, oxLDL & 
long-chain fatty acids 
Integrins 
β2-integrins 
 
 
 
         MAC-1 
Leukocytes
 
 
 
Polymorphonuclear 
leukocytes, NK cells, & 
mononuclear phagocytes
Firm adhesion to 
endothelium & platelets 
 
 
Pattern recognition 
receptor causes 
phagocytosis
ICAMs VCAM 
fibrinogen 
 
 
various 
 
 
β3-integrins 
 
 
      IIIII 
 
Platelets & 
neutrophils/endothelium 
 
Platelets 
 
Firm cell adhesion 
 
 
Aids in platelet 
activation 
 
Fibrinogen; ECM 
 
 
Fibrinogen, vWF and 
fibronectin 
Tumor necrosis factor family
CD40 
CD40L 
endothelium, leukocyte &
platelet 
Activates different 
endothelium, leukocyte 
& platelet function
CD40L
CD40; ǂIIbǃ3 on platelets 
Table 1. Major Receptor molecules in endothelium, platelet, and leukocyte interactions 
(Modified from Harrison, 2005) 
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Activated platelets propel inflammation, by forming platelet-leukocyte complexes which 
facilitate leukocyte migration into the arterial wall. Since the density of P-selectin  on 
platelets after activation is much higher than on endothelium, leukocytes are easily recruited 
to the adherent activated platelets (White, 2007). In these dynamics, the balance between 
homeostasis and inflammation is easily shifted to inflammation in a vicious cycle as soluble 
P-selectin, shed from activated platelets and endothelium, stimulate leukocytes to produce 
tissue factor which subsequently activates more platelets (Vicic & Weiss, 1983). In further 
interaction with leukocytes; polymorphonuclear cells adhere to platelets in a Mac-1–
dependent manner, inducing complex activation cascades in monocytes that promote 
monocyte or neutrophil adhesion, thrombosis, monocytic chemokine and cytokine release, 
or the oxidative burst of neutrophils (Rivera et al., 2009). See table 1. Among the many 
receptor pairs, that contribute to neutrophil activation in platelet-neutrophil interactions, 
there is neutrophil surface triggering receptor expressed on myeloid cells 1 (TREM-1) and 
platelet surface TREM-1 ligand, although not required for platelet-neutrophil aggregate 
formation, cellular interactions involving this receptor pair induce respiratory burst activity 
and IL-8 secretion in neutrophils which attract leukocytes and further activate other 
platelets (Minors, 2007).  
By no means are platelets, endothelial cells and leukocytes innocent bystanders; through 
years of evolution these eager to protect cells fight infection, hemorrhage and constant 
insults. In the theater of inflammation, as it often happens, we undergo friendly fire, which 
make our vessels harder but not tougher. Without regard to its etiology, the interactions 
between platelets, endothelial cells, and leukocytes as a result of platelet activation, 
endothelial dysfunction and leukocyte adhesion, causes inflammatory responses which lead 
to the origin and establishment of atherosclerosis. 
3. Platelets resourceful machinery in function 
Platelets are the smallest of the many types of cells in circulating blood, with an average size 
of only 2.0 to 5.0 μm in diameter, 0.5 μm in thickness, with a mean cell volume of 6 to 10 
femtoliters (Riddel, Jr. et al., 2007). Platelets are anucleate, discoid shaped blood cells that 
partake in pathophysiological roles like: hemostasis, thrombosis, clot retraction, vessel 
constriction/repair, inflammation and other aspects of host defense (Austin S.K., 2008). 
They are critical players in immune oversight and an important key to cellular interactions 
during the coagulation and inflammation process (Brass, 2010). Their sheer number, shape 
and small size make possible for platelets to localize to the vessel wall under flow, making 
possible a constant survey of the wall integrity (Coughlin, 2000). Platelets contain scarce 
functional mitochondria, glycogen, an intricate membranous system, and three major 
morphologically different, secretory organelles which are: ǂ-granules, dense core granules & 
lysosomes (Coughlin, 2005). Inside the ǂ-granules can be found a wide variety of 
coagulation/adhesive proteins, growth factors and protease inhibitors involved in both 
primary and secondary hemostatic mechanisms (Kahn et al., 1999). The platelet membrane 
is covered by a wide variety of mobile transmembrane receptors, including integrins (e.g., 
ǂIIbǃ3: II III), leucine-rich repeated receptors (e.g., GPIb/IX/V), G-protein coupled seven 
transmembrane receptors (e.g., PAR-1 and PAR-4 thrombin receptors) and C-type lectin 
receptors (e.g., P-selectin ) (Coughlin, 2000).  
Under normal conditions, hemostasis occurs by two independent, but related processes: the 
platelet activation pathway and the coagulation cascade (Sivaraman & Latour, 2011).  
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The primary role of platelets in hemostasis is the formation of an initial plug at the site of the 
vascular injury or as commonly known, primary hemostasis. The formation of a stable plug 
consists of three principal events: adhesion, activation and aggregation. When the vessel 
wall is damaged, it exposes the blood to subendothelial collagen and microfibrilis, which 
stimulate the initial step that allows platelet adhesion (Delvaeye & Conway, 2009). Adhesion 
is also mediated via von Willebrand Factor (vWF), a multimeric protein synthesized by 
endothelial cells that serves as a bridge between the tissue and platelets. vWF binds to both 
exposed collagen at sites of vascular injury and the platelet membrane glycoprotein Ib-V-IX 
(GPIb-V-IX) receptor complex (Romney & Glick, 2009). Platelet activation is caused by 
exposure of various agonists, such as thrombin, thromboxane A2 (TxA2), adenosine 
diphosphate (ADP), collagen, and arachidionic acid to their particular receptors (Perez-
Gomez & Bover, 2007). One example is the G protein-coupled receptors on the platelet 
surface whose ligand are TxA2 , ADP, and thrombin (Satran & Almog, 2003). 
The PARs are G-protein-coupled receptors that use a unique mechanism to convert an 
extracellular proteolytic cleavage of the receptor into a transmembrane signal (Eyre L. & 
Gamlin F., 2010), hence the derivation of the thrombin receptor activating peptide (TRAP). 
Human platelets express two different G-coupled protease activated receptors, PAR-1 and 
PAR-4, while mouse platelets express PAR-3 and PAR-4 (Brass, 2010). In human platelets, 
PAR-1 is a high-affinity receptor that is activated at low concentrations of thrombin, PAR-4 
is the lower-affinity receptor that mediates thrombin signaling at higher concentrations of 
thrombin than PAR-1 (Johns, 2004), but it initiates signaling for a more extended duration 
that its PAR-1 counterpart. The activation of both PAR-1 and PAR-4 is enough to trigger 
platelet secretion and aggregation (Cambien & Wagner, 2004).  
Activation of platelets results in a conformational change from normal disc shape to a 
compact sphere with long dendritic extensions called pseudopods, which facilitate platelet-
platelet interaction. This process alters the membrane permeability and allows the entry of 
calcium into the platelet cytosol, leading to integrin activation. Following platelet activation, 
the membrane receptor glycoprotein IIǃ/IIIǂ (IIǃ III) undergoes a conformational change, 
which takes us to the adhesion phase mediated by platelet IIIII binding to fibrin(ogen), 
allowing the formation of multiple stable crosslinks between adjacent platelets. The GPIb-
IX-V receptor complex and IIIII are two unique platelets receptors responsible of platelet 
adhesion and thrombus formation to regulate hemostasis (Furie & Furie, 2004).  
A revised model of hemostasis described by  Satran & Almog (Satran & Almog, 2003), 
emphasizes the role of different cell surfaces in the localization and control of the 
coagulation processes, this includes three overlapping phases: initiation, amplification, and 
propagation. Tissue Factor (TF) is the key initiator of coagulation and is expressed primarily 
by subendothelial mural cells and adventitial fibroblast in and around the vessel wall (Filice 
& Niewoehner, 1987). The initiation phase starts when exposed collagen causes 
accumulation and activation of platelets, while exposed TF initiates the process of 
generating thrombin through binding to factor VII, creating the tissue factor-factor VIIa 
complex (TF/FVIIa) (Spitznagel & Shafer, 1985). TF/FVIIa complex activates factor X, either 
directly or indirectly via factor IX, and transforms prothrombin into thrombin in small 
amounts that are insufficient to complete the process of fibrin formation. The amplification 
phase occurs after platelet adhesion to the initiation site while in a state of partial activation. 
At that point thrombin, generated in the initiation phase and responsible for activating 
coagulation factors V, VIII, and IX, binds to platelets enhancing both their binding to the 
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vessel injury and activation. In the propagation phase the generation of thrombin is 
continuous. Factor Xa production is maintained by intrinsic tenase complex which, consist of 
factor VIIIa the cofactor for factor IXa (Spitznagel & Shafer, 1985). These three overlapping 
phases allow a fibrin platelet clot to form over an area of injury; this clotting process is 
limited by negative feedback by activated protein C which inactivates factors Va and VIIIa to 
avoid thrombotic occlusion in surrounding normal areas of the vasculature. The formation 
of a stable hemostatic plug is possible by important platelets properties which include their 
shape, the secretory granules, high density regulatory and adhesion receptors, and the 
ability to promote thrombin generation (Goncalves et al., 2011). The coagulation cascade, 
although important to platelet activation, is outside of the scope of this review 
Platelet disorders can be divided into two categories: quantitative and qualitative. 
Quantitative defects are abnormalities in platelet number, whereas qualitative defects are 
abnormalities in platelet function (Siljander, 2011). This classification is somewhat random 
as some platelet disorders are characterized by both decreased number and function 
(Heijnen et al., 1999). Platelet defects such as storage granule diseases like Hermansky–
Pudlak & Grey platelet syndromes or Glansmann thrombasthenia in which the platelets lack 
IIIII are rare qualitative diseases.  
An important receptor in platelet interactions which has being studied in models of 
qualitative platelets defects is P-selectin  (CD62P), formerly known as PADGEM or GMP-
140, is a member of the selectin family of cell adhesion receptors, and as its name implies, it 
is a lectin that binds various sugar moieties (Castaman et al., 1996). P-selectin , is stored 
premade in the Weibel-Palade bodies of endothelial cells and the platelet ǂ-granules 
(Berckmans et al., 2001) and remains inaccessible when these cells are in the resting state 
(Wolf et al., 1999).  
Activation of either/or both platelets and endothelial cells brings P-selectin to the cell 
surface. Thus control of P-selection dependant interactions is conditional of the presence of 
P-selectin on the cell that is in the active state. Upon cell activation, P-selectin is translocated 
to the plasma membrane, mediating the interaction of stimulated platelets and endothelial 
cells with leukocytes though its interaction with P-selectin glycosylated ligand (PSGL-1). 
PSGL-1 is a constitutively expressed receptor on platelets, leukocytes, and a subset of 
lymphocytes (Heemskerk et al., 2002) (psgl-1 does bind E- and L selectin as well). P-selectin  
mediates the formation of preliminary platelet-leukocyte aggregates (Yang & Wilson, 1996). 
Early studies on P-selectin demonstrated that P-selectin mediated in vitro platelet-leukocyte 
interactions and induced leukocyte rolling in a flow chamber system (Elzey et al., 2003). 
These studies were confirmed in the P-selectin null mouse where leukocyte rolling was 
attenuated and neutrophil migration to the peritoneum was delayed (Amabile et al., 2010). 
The implications of these findings have been profound and have set the stage for us to 
discern the relationship between hemostasis and inflammation. 
4. Platelets as dedicated players in immune function 
The inflammatory process in the classical sense has been defined by the innate and adaptive 
systems where early contact to foreign invaders is mediated by the innate compartment and 
if the danger persists the adaptive compartment will assist. There is an intricate series of 
communication behaviors within and between these compartments that include physical 
interaction and a series of chemical signals which regulate the migration of the white blood 
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cell population. Although we understand many of the individual parts, the system as a 
whole gets very complicated. The innate immune response is designed as our first response 
by identifying pieces of our puzzle that just don’t fit. Using a series of basic pattern 
recognition receptors, the innate immune system identifies foreign substances and seeks to 
destroy or remove them from our body. The cells of the innate immune system have a 
complicated system of chemical communications that act as sentinels attractants or 
differentiation agents that push the limits of the innate immune system to adapt to the 
problem at hand. Traditionally, natural killer cells, monocytes, monocyte derived cells and 
polymorphonuclear cells (a vast majority of which are neutrophils) form the major portion 
of our innate immune system. Complement is a series of soluble factors that form a cascade, 
similar to the serine proteases of the coagulation cascade, that results in lysis of microbial 
and apoptotic cells. Platelets not having the ability to rearrange receptors to acquire antigen 
specificity and having the ability to respond quickly to insult would be considered a 
member of the innate immune system. 
4.1 Platelet regulation of neutrophil function 
Foreign invaders are recognized by neutrophils and neutrophils are considered to form our 
first line of defense (Puddu et al., 2010). Next to platelets, neutrophils are the most 
numerous white blood cells in our body and they are innate immune effectors. Neutrophils 
are dangerous to foreign substances as well as to ourselves if left unchecked. When they 
identify foreign invaders they use one of several killing mechanisms to dispose of the 
identified threat. Neutrophils will phagocytose bacteria or when the conditions are right 
they will release their granule contents causing non-specific damage to the quarry as well as 
the host (Chen et al., 1995). Here we will argue that even though neutrophils MAY be our 
first line of defense, they need platelets to regulate their decision making at point of 
endothelial contact (figure 1). Platelet regulation of neutrophil function is best introduced by 
evaluation of platelet depletion studies.  
 
 
Fig. 1. Do platelets maintain vascular integrity preemptively by regulating neutrophil 
function? 
Over the past five years, a wealth of investigators has used platelet depletion in mouse 
based disease models to better understand the platelet’s role in inflammation. These studies 
have begun to show that the depletion of platelets leads to abbreviated neutrophil derived 
inflammation and neutrophil transendothelial migration. For example, using a corneal 
epithelium abrasion model, (Lam et al., 2011) demonstrated that platelet depletion lowers 
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neutrophil transmigration across corneal endothelium at six and twelve hours. Using P-
selectin glycosylated ligand (psgl)-1 null mice Zarbock et al. implicate the psgl-1/P-selectin 
ligand pair as a key regulator in the connection between platelets and neutrophils. In 
models of acute lung injury, platelet depletion reduced neutrophil influx (Zarbock et al., 
2006). Zarbock and colleagues show that platelets recruit neutrophils to the lungs and use P-
selectin and TxA2 dependant mechanisms to mediate damage. TxA2 is an arachadonic acid 
derived inflammatory mediator librated from activated platelets (Zarbock et al., 2006). 
Using a two hit lung injury model Looney et al., demonstrated that platelet depletion 
actually seemed to improve survival outcomes (Looney et al., 2009). The two hit model was 
shown to be P-selectin independent, but the investigator’s use of aspirin, which lowered 
lung injury and improved survivorship supports a role for TxA2. Aspirin inhibits TxA2 
production from platelets. Kornerup et al., used two different models (LPS inhalation and 
xymosan induced peritonitis) to show that platelet depletion reduces neutrophil recruitment 
to the inflammatory site in the lungs and the liver (Kornerup et al., 2010). Their data 
suggests that platelets activate the neutrophils forming platelet/neutrophil complexes 
which aid in neutrophil transmigration. Depletion of platelets was also shown to lower 
recruitment of eosinophils and lymphocytes in allergic inflammation (Pitchford et al., 2005), 
and apparently increases the efficacy of breast cancer chemotherapy (Demers et al., 2011). 
Taken together, therapeutic targeting of inflammation may need to focus on platelet 
function in addition, if not totally, to control the immune response. 
A recent platelet derived mechanism that was identified is the neutrophil extracellular traps 
(NETs: (Clark et al., 2007), in which the toll like receptor on platelets recognizes its ligand 
and mediates platelets to influence to neutrophils to release their DNA. The DNA is used to 
ensnare bacteria in the lungs and liver sinusoids. Neutrophils are born to die protecting 
their host, in many ways they are like larger nucleated platelets performing many of the 
same functions including: aggregation, microparticle release, and phagocytosis, with the 
addition of the ability to extravate into the tissue. There are two points to be made here: first, 
in the neutrophil NET study, they demonstrate that platelet recruitment to the lungs during 
sepsis is neutrophil dependent, a finding that is in stark contrast to the work by Zarbock, 
where they show the opposite. Secondly, they clearly show a different outcome as a result of 
platelet-neutrophil interactions. Why were these outcomes so very different, although they 
used similar stimulants (LPS)? 
4.2 Monocytes and platelets line up to work against infection 
The second part of the innate immune system is monocytes and monocyte derived cells 
(macrophages). Monocytes are innate immune regulators with the responsibility to clean up 
the debris left from dying and apoptotic neutrophils that have engaged in battle. Monocytes 
usually arrive to scenes of inflammation after neutrophils and platelets and will persist in 
the inflamed tissue until the infection subsides. The expression of tissue factor by monocytes 
will attract the coagulation factor VIIa and is believed to be a primary cause for the initiation 
of the coagulation cascade and subsequent deregulation of hemostasis during sepsis. 
Monocytes, however, are also the primary link between the innate and the adaptive immune 
system (Ziegler-Heitbrock, 2007). Monocytes maintain the ability to differentiate into tissue 
macrophages or dendritic cells which present antigen to lymphocytes and prime the 
adaptive immune system. Once in the tissue, monocytes quickly mature into tissue 
macrophages and they are often referred to by a different name, dependant on the tissue. 
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For example the resident macrophage of the liver is called the Kupffer cell. Tissue 
macrophages release a battery of cytokines and chemokines that gage the enormity of the 
task at hand using chemoattractants to call in neutrophils, platelets, or more macrophages if 
deemed necessary. In a model of sepsis, where LPS from Klebsiella was given intravenously, 
Kupffer cells were shown to be responsible for the recruitment of platelets to the liver 
(Yamaguchi et al., 2006). However, in a model of Leishmaina major, platelets were 
demonstrated to recruit monocytes indirectly through the release of platelet derived growth 
factor (PDGF) (Goncalves et al., 2011). The model that the Goncalves et al., puts forth 
suggests that the release of PDGF from activated platelets cause a release of the cytokine 
CCL2 from a multitude of cell types which in turn attracts monocytes. Platelet depletion 
reduced the accumulation of effector monocytes and reduced clearance of Leishmanina, 
therefore demonstrating the importance of platelets in the removal of parasitic infections. 
Interestingly, platelet activation was dependent on complement factor 3 (C3), allowing us to 
address in the next scene in our drama, platelet interaction with complement. 
4.3 Complement and new pathways in platelet function 
Complement is a major immune regulation pathway. The complement system is ancient, 
abundant, and redundant (Ricklin et al., 2010). Not only is the system ancient, so has been 
our understanding of complement until recently. The biochemical origin of our 
understanding of complement is revealed by the terminology used with complement 
components, which are called factors. Much like the coagulation system where fractions of 
blood components with activity were isolated and its activity was given a number; our 
understanding of the complement system has grown from these obscure beginnings. 
Molecular genetics has breathed new life into our understanding this, one of our oldest and 
most conserved systems. In immunity, complement is a major component in the control of 
bacterial infection. In a process called, opsonization, a cascade involving a series serine 
proteases and proteins result in a membrane attack complex or MAC that forms pores on 
foreign cells such as bacteria and apoptotic cells and is chemoattractant to white blood cells. 
Complement in its most basic sense is focused around factor C3 (Lambris et al., 2008). There 
are three major pathways that lead to the formation of C3 activators or convertases. These 
pathways are the lectin, classical, and alternative pathways. The lectin pathway is activated 
by the mannose binding protein leading to the formation of the C3 convertase 4b2b. 
However, to date not much information in regards to the lectin pathway and platelets is 
published and we will focus this portion of the review on the classical and alternative 
pathways of complement activation. 
The classical pathway is most commonly activated when complement factor C1q interacts 
with IgG or IgM (MacKenzie et al., 1971). The binding of C1q to immunoglobulin allows the 
complement/Ig complex to activate components C1r and C1s, leading to the cleavage of C4 
and C2. C4 is cleaved into C4a and C4b. While C4a diffuses away, C4b is momentarily 
enzymatically active and may form covalent bonds with the complement/Ig complex or 
bind to endothelial cells. In the event that neither of these options happen, the interaction of 
C4b with the surrounding water converts C4b into a ligand for C2 allowing C2’s conversion 
into C2a and C2b by C1s. C2b bound to C4b forms the C3 convertase C4b2b cleaving the 
central complement factor C3 into C3a and C3b. (there is controversy in the literature to 
nomenclature of the C4b2b convertase, in some references it is called C4b2a). Platelets 
contain C1q and have demonstrated activity of the classical pathway (Nayak et al., 2010; Yin 
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et al., 2007). Platelet activation of the classical pathway is associated with anti-phospholipid 
syndrome and immune thrombocytopenia purpura (Peerschke et al., 2010). 
The alternative pathway is responsible for up to 95% of the activated C3b (Bexborn et al., 
2008). The tick over theory provides a model for the activation of the alternative pathway. 
C3 is relatively dormant in circulation; however a small amount is spontaneously activated 
to C3H2O, and provides windows of opportunity for C3 to behave essentially as a pattern 
receptor recognizing potentially harmful substances. C3H2O is primed to bind factor B and 
subsequently cleaved by factor D into C3a which is chemoattractive and the C3 convertase, 
C3b (Fearon et al., 1973; Fearon & Austen, 1975). Under the correct circumstances C3b will 
insert into cells causing an increase in deposition of C3b eventually tipping the scales 
toward complement opsonization of cells and initiation of the complement cascade (Bexborn 
et al., 2008). Increased C3b activates C5 leading to the deposition of the C5-9 membrane 
attack complex (MAC), which functions to produce pores in cells eventually leading to cell 
destruction. 
Opsonization of cells by C1, C3b and C5b can also lead to phagocytosis when complement 
bound cells are recognized by their corresponding receptors (Ricklin et al., 2010). CD35 
(CR1), which is found on many white blood cells and in the granules of neutrophils, 
recognizes C3b and C4b deposited on cells mediating phagocytosis. The integrins CD11b 
(CR3) and CD11c (CR4: both of these integrins are complexed with CD18 (Gahmberg, 1997)) 
mediate binding to complement iC3b which is the inactivated form of C3b, and mediates 
phagocytosis as well (Arnaout, 1990; Ross, 2000). Although CD11c is constitutively 
expressed on neutrophils both CD11b/CD18 complexes and CD35 are stored in neutrophil 
granules and are upregulated on activated neutrophils. When deposition of complement is 
in the endothelium, neutrophils are prompted to release their granules and phagocytize 
opsonized cells (Yin et al., 2007). It is suspected that complement deposition is a major cause 
of loss of vascular integrity, edema, and bleeding associated with inflammation. 
Tight regulation is maintained on complement. An overzealous complement system will 
lead to self-attack of endothelium and may be an initiation factor of pathways leading to 
hemorrhage. Factor I (fI) is a major inhibitor of C3b and in conjunction with Factor H (fH) 
mediate the deceleration of the MAC formation. Factor H is a cofactor in fI binding and 
deactivating C3b that has bound the cell surface (Paixao-Cavalcante et al., 2009). Once 
bound, active C3b is transformed to iC3b which stops further opsonization, iC3b becomes 
the ligand of neutrophils and monocytes expressing CD11b or CD11c. Oddly enough, CD35 
while initiating phagocytosis also mediates inactivation by fI (Ricklin et al., 2010).  
Mutations in factor H are associated with hemolytic uremic sysdrome (HUS) (Licht et al., 
2009; Stahl et al., 2008). Studies in fH deficient mice show that platelets are in large part 
responsible for this association. Platelets are a sink for fH (Vaziri-Sani et al., 2005). Platelets 
uptake fH from the plasma and store fH in various locations including the ǂ-granules 
(Devine & Rosse, 1987; Licht et al., 2009). Mutations in fH lead to increased complement 
deposition on platelets and increased platelet activation (Stahl et al., 2008). These findings 
are consistent with the thrombocytopenia and thrombus formation seen in the kidneys of 
HUS patients. 
Platelets are not immune to opsonization and there are numerous reports of complement 
binding to platelets, but these waters remain murky. Upon platelet activation there is a 
drastic increase in the binding of each of the anaphalaxins (C3b, C4b and C5 - 9) as well as 
C1q (Peerschke & Ghebrehiwet, 1997). Furthermore, P-selectin has recently been shown to 
propagate C3 activation opening a point of possible crosstalk between the hemostatic and 
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innate immune systems (Del Conde et al., 2005). Subsequent studies, however, suggest that 
even though C3 binds to activated platelets it doesn’t necessitate proteolytic activation. The 
C3 associated with platelets was estimated to be C3H2O containing an exposed thioester, 
which in the presence of fH and fI is inactivated rapidly (Martel et al., 2011). Coincidently, 
the C3 associated with the platelets facilitated binding of a soluble CR1, consistent with the 
idea that platelets facilitate the inactivation of the C3H2O. In fact, in support of this idea, 
Martel et al. demonstrate that the C5-9 complex will form on less than 15% of platelets 
indicating that the MAC pathway is not a major form of platelet destruction or mechanism 
of platelet immune crosstalk (Martel et al., 2011). They suggest that the binding of the C5–9 
complex may contribute to micropartical formation. Thus the binding and activation of C3b 
by P-selectin may need additional triggers such as sheer to induce C3 activation.  
The studies in patients with aHUS strongly suggest that the regulation of C3b is a major 
mechanistic contact point between the immune and hemostatic systems. Platelets from 
patients lacking a functional fH, have increased deposits of C3 and C5–9 and are subject to 
complement mediated activation. As mentioned above, aHUS patients have the tendency to 
develop microthrombi in their kidneys that lead to kidney damage and accordingly they 
suffer from thrombocytopenia (Hirahashi et al., 2009; Stave & Croker, 1984). Thus, the ratio 
between C3 and fH represent the delicate balance that has to be overcome for complement 
to involve platelet participation. Early sepsis studies demonstrated that C3 depletion 
alleviated the thrombocytopenia associated with the sepsis response (Ulevitch & Cochrane, 
1978), supporting the notion that from the immune system, it is C3 that initiates the 
participation of platelets. Here we submit that the complement cascade is the 
immunological system’s major pathway to platelet participation (see figure 2). Complement 
activates platelets in a manner similar to the coagulation system, but with less of a robust 
reaction. A complement derived platelet activation cascade would not be to form an 
occlusive clot but localized thrombi, such as that to contain bacterial infection. Complement 
activation may lead to differential release of specific subsets of platelet -granules (Italiano, 
Jr. et al., 2008). When platelets are depleted, complement activation leads to hemorrhage 
(Goerge et al., 2008). 
 
 
Fig. 2. Platelets are activated by both coagulation and complement cascades. The 
complement cascade represents the immune systems access to platelet function. 
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4.4 Adaptive immunity 
Although we will not focus on adaptive immunity in this review, we will mention that 
lymphocytes comprise our adaptive immune system. Lymphocytes produce molecules that 
are derived to specifically recognize foreign potentially dangerous substances. Humoral 
immunity, mediated by B-cells, involves the production of antibodies. B-Cells will produce 
classes of antibodies that specifically recognize regional markers on foreign substances and 
cause clustering of the identified antigen into immune complexes (ICs). ICs can be bound by 
complement and targeted for destruction, or are directly removed by the cells of our innate 
immune system which include neutrophils and monocytes. 
Oddly enough, the antibodies produced by B-cells are made in a sequential manner. For 
example, the pentametric IgM class is made first. IgM is subsequently changed to dimeric 
IgG in a process called class switching. Class switching is regulated by the CD40-CD40 
ligand (CD40L)  interaction. Mice lacking CD40L develop a hyper IgM syndrome, where the 
B-cells fail to change from production of IgM to IgG. CD40L is expressed on platelets and is 
believed to be a major source of CD40L. Transfer of wild type platelets to CD40L null mice 
rescues this syndrome, demonstrating an important regulatory role for platelets in the 
adaptive immune system (Elzey et al., 2003). 
T-lymphocytes or T-cells mediate cellular immunity through a T-cell receptor that is made 
to specifically recognize one antigen. The T-cell receptor directs the T-cell to its antigen 
where it mediates a supportive function (T-helper cells) or can mediate cytotoxicity 
(cytotoxic T-cells). Cytotoxic T-cells recognize cells in distress such as cancer or virally 
infected cells. Using two different models of hepatic viral infection Iannacone et al. 
demonstrated that platelet depletion during a hepatic viral infection lowered the amount of 
cytotoxic T-cells that entered the liver and lowering hepatic cell damage. However, even 
though there was reduced liver damage, viral clearance was also reduced. Reintroduction of 
activated platelets restored the hepatic damage, but also allowed the viral load to be 
removed (Iannacone et al., 2005). In the theatrical setting of adaptive immunity, platelets 
demonstrate an indispensible role. 
5. Platelet derived microparticles fuel the inflammatory response 
Microparticles are plasma membrane-derived vesicles shed from stimulated cells which 
include leukocytes, erythrocytes, endothelial cells, various cells in the central nervous 
system (CNS), adipocytes and platelets (Siljander, 2011). Platelet microparticles (PMP) are 
small membrane-coated vesicles which circulate in the blood stream. PMP are estimated to 
vary in size from 0.1–1.0 μm with the smaller particles originating from ǂ-granules and the 
larger particles being derived from the plasma membrane (Heijnen et al., 1999). There is 
increasing evidence that these submicron fragments, termed microparticles, have important 
physiological roles. A good example is Castaman defect, which is a deficiency in the ability 
to generate platelet microparticles from platelets that is associated with a bleeding tendency 
(Castaman et al., 1996). 
PMP constitute for approximately 70-90% of all microparticles (Berckmans et al., 2001). 
Recently it was found, that megakaryocytes generate microparticles. Using a system where 
particles bearing CD62 or LAMP-1 were considered to be platelet derived and those that 
expressed filamin A were megakaryocyte derived. Flaumenhaft et al., determined that the 
microparticles circulating in healthy individuals are surprisingly predominantly 
megakaryocyte derived (Flaumenhaft et al., 2009). Characterization of microparticles, using 
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proteomics and functional approaches, has shown that PMP can be separated into different 
size classes. Each of these size classes can differ in protein components, protein/lipid ratio, 
and functional effects on neighboring platelets and endothelial cells. When separated by 
centrifugation, PMP can be separated into four fractions: two of which (fractions 2 and 3) the 
phospholipid/protein ratios are typical of the plasma membranes, while the composition of 
fractions 1 and 4 indicate a greater proportion of lipid (Dean et al., 2009). The study of PMP 
has evolved rapidly, putting them as central mediators of many physiological processes 
such as inflammation. This part of the chapter will describe the origin of PMP and discuss 
their role in the inflammatory process under different conditions. 
PMP are mainly released by the ǂ-granules and multivesicular bodies of activated platelets, 
having exposed phosphatidylserine (PS), and resembling apoptotic cells. In a cell, 
aminophospholipids such as PS and phosphatidylethanolamine (PEA) are specifically 
segregated on the internal leaflet of the plasma membrane, whereas phosphatidylcholine 
and sphingomyelin are enriched on the external one. The greater proportion of PS exposed 
on the surface of activated platelets is reflected in PMP derived from the platelet membrane. 
A significant and sustained increase of cytosolic Ca2+ accompanying cell stimulation may 
lead to the collapse of the membrane asymmetry by stimulating scramblase and floppase 
enzymatic activities and concomitantly inhibiting the flippase. The mechanisms involved in 
PMP release include platelet activation, which is calcium-dependant and Bak/Bax/caspase 
mediated release, which is independent of platelet activation (Schoenwaelder et al., 2009). 
The calcium dependant mechanisms involve membrane fragmentation or blebbing, loss of 
membrane integrity, microvesiculation, and the exposure of PS on the platelet surface 
followed by release of the PMP caused by cytoskeleton degradation of filamin 1A and 
gelsolin by Ca2+-dependent calpalin (Wolf et al., 1999). Bak/Bax mechanisms described by 
Schoenwaelder et al., showed that prosurvival Bcl-xL maintains platelet viability, primarily 
by restraining the pro-apoptotic function of Bak (Schoenwaelder et al., 2009). It has been 
reported that Bcl-xL levels decline in stored platelets. This is consistent with an increase of 
PS exposure seen in platelets, a process which requires the Bak/Bax proteins, which play a 
central role in apoptosis. The release of PS expressing PMPs increases platelet procoagulant 
activity. Accordingly, the mechanisms of PMP release affect the size, constituents and 
function of the PMP. 
5.1 Functional importance of platelet microparticles 
PMP function is largely defined by the receptors and any molecules trapped in and on the 
vesicle at the time of release. PMP reflects a subset of the total receptors on the platelet 
surface or from the platelet -granules at any given time. The major functional significance 
of these bioactive vesicles is associated with its procoagulant activity. For example, PMPs 
are enriched with membrane receptors for coagulation factor Va and the fibrinogen receptor 
II III. When PS is exposed on the surface of activated platelets, membrane assembly of 
coagulation factor complexes occurs (Heemskerk et al., 2002). The presence of factor Va and 
PS form the foundation of the tenase complex and facilitate the assembly of the 
prothombinase complex. PMPs with II III facilitate polymerization though the binding of 
fibrin forming mini scaffolding stations that support the generation of thrombin. Together 
these molecules provide a catalytic surface for the prothrombinase reaction, thus 
contributing to the acceleration of thrombin generation (Ando et al., 2002). PMPs can also 
become membrane templates for fibrinolytic and proteolytic factors as well. 
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5.2 PMP and disease 
CD40 is a receptor expressed on a wide range of cells such as B cells, neutrophils, 
monocytes, macrophages, platelets, dendritic cells, endothelial cells, fibroblast, keratinocytes 
and smooth muscle cells; modulating humoral and cellular immunity. As a member of the 
tumor necrosis factor (TNF) superfamily, the activation of CD40 by CD40L (CD40L/CD154) 
plays a crucial role for the development and progression of a variety of inflammatory 
processes including T-cell priming, enhanced T-cell cytotoxicity, and T-cell depended B-cell 
responses (Yang & Wilson, 1996). As mentioned above, platelets express CD40L. Matrix 
metalloproteinase-2 (MMP-2) releases CD40L from the platelet membrane creating the 
bioactive soluble fragment, sCD40L. Platelets are responsible for the production of 
approximately 95% of sCD40L in the peripheral blood (Elzey et al., 2003). Furthermore, 
CD40L is found on PMP which implicates PMPs in several diseases. Multiple sclerosis (MS), 
for example, is characterized by the formation sclerotic plaques in the central nervous 
system. During MS, the cells responsible for the production of myelin sheaths, 
oligodendrocytes, are destroyed. Auto reactive T cells attack the sheaths, causing neuronal 
destruction. In the case of MS, chronic platelet activation leads to the release of CD40L, 
implicating PMP as a potential effector in the development of MS.  
The autoimmune disease, rheumatoid arthritis (RA),  manifests as a chronic inflammation of 
the synovial lining in the joints, which results in pain, swelling and in the most severe cases 
a destruction of the bone and cartilage. In an elegant study, Boilard et al., implicate PMPs in 
the pathology of RA. They were investigating the presence of platelets in the synovial fluid 
of RA patients. Using flow cytometry and the platelet specific marker, CD41 to detect the 
platelet specific integrin IIIII, they demonstrated an average of 2x105 PMP/l in RA 
patients compared to non-detectable levels in patients with osteoarthritis. Interestingly 
enough there were a subset of platelets that rosetted the leukocytes that were present in the 
synovial fluid (Boilard et al., 2010). RA can be induced in mice by the passive transfer of 
immunoglobulin G (IgG) auto-antibodies from K/BxN mice to wild type. Using the K/BxN 
system, the authors demonstrated that platelet depletion greatly reduced arthritic 
symptoms, supporting a role for platelets in the progression of RA. They subsequently 
determined using glycoprotein VI (GPVI) deficient mice that the microparticles were 
generated by activation by collagen and that these PMPs contained the ability to release IL-
1. IL-1 subsequently induced proinflammatory cytokines IL-6 and neutrophil 
chemoattractant IL-8 production leading to the recruitment of neutrophils. Thus, PMP are 
major regulators of RA. The finding answered several nuances found in patients with RA. 
For instance how come patients with RA have platelet proteins in their synovial fluid but no 
platelets? Here the aerosolized platelets in the form of PMP delivered discrete packets of 
platelet function resulting in bone damage and the recruitment of neutrophils by an indirect 
method. 
Therefore, aerosolized PMPs allow the delivery of skewed platelet function as opposed to 
the complete regulatory balance of platelet function. The recruitment of inflammatory cells 
at the sites of vessels injury can drive the development of arthrosclerosis, in which the 
participation of PMP is mostly the formation of the plaque and its progression (Amabile et 
al., 2010). PMP participate by amplifying and sustaining coagulation and inflammatory 
response after the rupture of the plaque (Puddu et al., 2010). -amyloid, for example, is 
found in PMP and is implicated in the progression of Alzheimer disease. Platelets are the 
major source of -amyloid in the peripheral blood (Chen et al., 1995). In fact, it was shown 
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that -amyloid secretion supersedes that of all other proteins shed from the platelet surface 
upon activation (Fong et al., 2011). Accordingly, PMPs have been cited as carriers of soluble 
Alzheimer’s beta amyloid (Matsubara et al., 2002). In the case of cancer PMP contributes to 
the metastasis by producing MMP and VEGF (vascular endothelial growth factor) among 
other important factors. Following a paradigm where platelets are strictly hemostatic 
vessels, the delivery of PMP would strictly cause coagulatory disarray. However, here we 
show that while PMP does play a coagulatory role in situations like atherosclerosis, they 
also play diverse role like those seen with activation of T-cells or exacerbation or RA in the 
synovial fluid of joints. PMPs may be important force working toward unresolved 
inflammation as described by Khatami, where two opposing inflammatory forces (wound 
healing and apoptotic) are shifted leading to a chronic inflammatory state (Khatami, 2011). 
6. Immunohemostasis 
Our laboratory’s interest in the intersection of inflammation and hemostasis is derived from 
the study of a platelet specific gene that mediates platelet involvement in inflammation 
called TREM-Like transcript (TLT)-1 (Washington et al., 2002). TLT-1 is a single Ig domain 
receptor found on platelets and megakaryocytes (Barrow et al., 2004; Washington et al., 
2004). Like the adhesion molecule p-selectin, TLT-1 is stored in the platelet ǂ-granules until 
activation when it is quickly bought to the surface (Washington et al., 2004).  
6.1 TLT-1 
The TLT-1 gene (treml-1) is situated in the TREM cluster, amongst a group of 
immunoregulatory receptors that are found on leukocytes and endothelial cells (Allcock et 
al., 2003). TLT-1 is the first member of the cluster found on platelets giving it a unique role 
among the TREM family of genes (note; TLT-2 has recently been found in platelet releasates 
suggesting it is present on platelets; (Fong et al., 2011)). There are two published forms of 
TLT-1 which include a long form that has several interesting motifs in the cytoplasmic 
domain and a splice variant form that only has a 16 amino acid tail (Allcock et al., 2003; 
Washington et al., 2002). Interactions with the phosphatases SHP-1, -2 and moesin have 
been described but the significance of these interactions have not been uncovered (Barrow et 
al., 2004; Washington et al., 2002). Nevertheless, an activation role for TLT-1 was supported 
when single chain antibodies specific to TLT-1 were shown to inhibit platelet aggregation in 
the presence of low levels of agonist in vitro (Giomarelli et al., 2007). These results support 
an enhancing role for TLT-1 and suggest that TLT-1 may play an important role in 
maintaining platelet activation. 
To better understand TLT-1’s potential in vivo, a null mouse model was developed 
(Washington et al., 2009). The TLT-1 mouse is viable with negligible differences seen in 
platelet counts. During platelet aggregation assays we found that the null platelets show 
reduced capacity for aggregation with the secondary platelet agonists ADP and the TxA2  
mimetic U46619 compared to wild type (wt). Consistent with these results, tail bleeding 
assays demonstrate and overall increase in time to secession of bleeding compared to wild 
type mice, however the difference between null and wt mice were not as substantial as a 
PAR1 or GPVI null mouse suggesting that TLT-1’s role in hemostasis was not of primary 
hemostasis, but one that was “unique”. 
To gain a clearer picture of TLT-1 function we used an acute sepsis model where we inject 
LPS intraperitoneally and monitored hemostatic and immunological parameters as well as 
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survival (Washington et al., 2009). Sepsis is an interesting model because it starts with a 
strictly immunological challenge and mortality is a direct response to rife platelet activation 
and microthrombi. Platelets play an indispensible role during hemostasis and an often 
unappreciated role during inflammation (Levi & van der Poll, 2004). The involvement of 
platelets in the immune response and sepsis is undeniable, but never the less not completely 
understood. 
Treatment of null and wt mice with LPS causes the TLT-1-/- mice to succumb faster and in 
greater numbers to the immunological challenge. Null mice display a distortion of both 
hemostatic and immunological parameters. Plasma levels of one of the major inflammatory 
mediators, tissue necrosis factor- ǂ (TNF- ǂ), is also elevated in the null mouse, 
demonstrating TLT-1 either directly or indirectly modulates immune function. Platelet 
counts in the null mouse are significantly lower, while the levels of d-dimers are elevated. 
These two important markers of sepsis, platelet count and d-dimers, suggest the presence of 
a more severe DIC in the null mouse than wt (Washington et al., 2009). 
The severity of DIC in the null mouse compared to the wild type mouse was further 
supported in the localized Shwartzman model of vasculitis. The localized Shwartzman 
reaction, which correlates well with the presence of DIC in humans, challenges the animal 
subcutaneously with the inflammatory mediators LPS and TNF-ǂ and subsequently the 
lesion is evaluated for hemorrhage, clotting, and leukocyte infiltration. Null mice showed 
slightly increased amounts of microclots, and neutrophil infiltration, however the quantity 
of hemorrhage was twofold and the area of the lesion was almost three fold greater than in 
wt mice (Washington et al., 2009). These results are indicative of a role in the integration of 
inflammation with hemostasis; however at the time, this idea, although reported in 
numerous publications, was not quite accepted. 
6.2 Immune – Hemostasis 
It was in a series of articles originating from the Wagner laboratory that light was shed on 
the connection between inflammation and hemorrhage. In essence they asked, “When you 
are thrombocytopenic, where do you bleed?” A surprising answer was in inflamed tissue 
(Goerge et al., 2008). In a series of eloquent experiments they provide convincing evidence 
that platelets are necessary to control immune derived bleeding, and what’s more they 
(platelets) use other than the classical hemostatic mechanisms involved in plug formation. 
Using the reverse arthus model significant hemorrhage is witnessed only in the group of 
mice that are thrombocytopenic, confirming the importance of platelets to immune-
hemostasis. The authors go on to show that deletion mutants for II III, GPIV, GP1b, or p-
selectin, like wt mice,  maintained their ability to control hemorrhage, demonstrating that 
the members of the classical pathways of platelet function are not necessary to mandate an 
immune-hemostasis; signifying that there are alternate pathways to hemostasis. They also 
used a LPS inhalation model to show that mice that are thrombocytopenic bleed in the lungs 
demonstrating the hemostatic effect at the organ level (Goerge et al., 2008). Both of these 
models induce complement deposition, neutrophil activation, and endothelial damage that 
ultimately recruit platelet involvement. It is easy to imagine that the bleeding diathesis 
could be reproduced by the inhibition of only a handful of specific molecules important to 
the cause, which in essence is what they were testing with the deficient mice in the reverse 
arthus model. 
The mechanisms that regulate the hemorrhage seen at sites of inflammation and in cancer 
seem to be similar. In a cancer model, it was shown that the addition of resting platelets, but 
www.intechopen.com
The Platelet as an Immunomodulator: The Old Thespian with 
New Roles in Atherosclerosis, Sepsis and Autoimmune Disease 
 
113 
not activated platelets, rescues the hemorrhage seen during inflammation in cancer. One of 
the major differences between resting and activated platelets is that resting platelets 
maintain the contents of their -granules and accordingly, they go on to show that 
supernatants from activated platelets will rescue the bleeding seen at a tumor. These results 
indicate that platelet -granules contain a soluble factor or factors that have the ability to 
maintain vascular integrity at sites of hemorrhage induced by inflammation. Although they 
were able to show distinct changes of various culprit -granule proteins, their work did not 
reveal the protein or proteins responsible for the control of hemorrhage (Ho-Tin-Noe et al., 
2008). Their conclusion is that platelets continually maintain hemostasis in the face of 
inflammation using mechanisms other than those well described during plug formation. 
This opens the idea that platelets may work preemptively to stop hemorrhage by regulating 
leukocyte activity at the vessel wall. So the question remains, is there a molecule or a hand 
full of molecules responsible for maintaining hemostasis in the face of inflammation? 
These series of experiments clearly define what we have known since the time of Celsius, 
but have ignored. In light of these experiments, our interpretation of TLT-1’s “unique” role 
becomes plausible. TLT-1’s purpose on platelets appears to be that of transition. In 
conjunction with molecules like p-selectin, GpIb, and TREM-1, TLT-1 mediates the 
integration of inflammatory signals with platelet function, mediating coagulation when only 
secondary agonists like TxA2 or low levels of thrombin are present. TLT-1 may be one of a 
handful of molecules regulating immuno-hemostasis. These eloquent experiments (Goerge 
et al., 2008; Ho-Tin-Noe et al., 2008; Ho-Tin-Noe et al., 2009) also call for an official 
beginning of a new field that defines the intersection between immunology and hemostasis, 
one that we refer to as Immunohemostasis.  
It is no longer adequate to state that platelets are linked to the inflammatory response. Here 
we have outlined numerous publications that demonstrate: how platelets influence 
neutrophil function (Clark et al., 2007; Looney et al., 2009; Zarbock et al., 2006), monocyte 
function (Goncalves et al., 2011), both T and B cell function (Elzey et al., 2003; Iannacone et 
al., 2005), the interrelation with complement and the effect of microparticles on the immune 
system (Boilard et al., 2010). These studies clearly demonstrate that platelets play an 
important role in inflammation. What is called for now is the kinetics of interactions and 
outcomes from studies using enhanced or decreased platelet count in immune reactions. 
While all of the studies mentioned point out that platelets influence immune function, very 
few point out the outcomes from having increased or decreased platelet involvement. We 
pointed out earlier in this discussion, seemingly conflicting results between studies with 
similar stimuli but that had with different outcomes. Using LPS, Zarbock et al., show that 
platelet depletion decreases inflammation. Clark et al., uses LPS and show that platelets are 
critical for NET formation. Why are they different and do they connect?  Zarbock et al., looks 
at a 2 hour time point (Zarbock et al., 2006) where Clark et al., uses longer time points (Clark 
et al., 2007). NETS are notoriously slow in formation (Massberg et al., 2010); therefore these 
two results could be different stages of the same continuum. Neither of the articles describes 
outcomes, but leave open for debate which comes first, the platelet or the neutrophil. 
Looney et al.,  (Looney et al., 2009) show an acute lung injury model where platelet depletion 
decreases mortality, but they used a two hit model where LPS was followed by antibodies to 
MHC. It is easy to see how platelet depletion could be life preserving. Their studies 
however, suggest that it is the neutrophils that recruit the platelets. 
In reports that do report outcome, they show that even though platelet depletion reduces 
inflammation, they also point out that without the platelets, the immune response was 
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inadequate. In the Leishmania study for example, platelet depletion lowered monocyte 
recruitment and inflammation, but at the same time the Leishmania infection was not cleared 
(Goncalves et al., 2011). In the thrombotic glomerular nephritis model, platelet depletion 
increased lethality of the treatment suggesting that platelets play a protective role. Similar 
outcomes were seen with viral models, where platelets caused hepatic damage and removal 
of platelets reduced the damage. Iannacone et al., demonstrated that although there was less 
damage without platelets, the T-cells were unable to remove the viral infection, 
demonstrating that platelets are a critical part of the inflammatory response (Iannacone et 
al., 2005).  
In a final note, it was shown that coagulation was important in bacterial immune response 
to help contain the infection (Massberg et al., 2010). It was ascertained that neutrophils 
release nucleosomes containing serine proteases. These nucleosomes function to make NETs 
and also that degrade platelet derived tissue factor pathway inhibitor, thus shifting the 
hemostatic balance at the platelet neutrophil interface toward coagulation. The authors 
point out the conserved nature of coagulation’s role in controlling infection in stating that 
insects don’t have an adaptive immune system and use coagulation as a mechanism to 
control infection in the hemolymph. Therefore they maintain that coagulation is an 
evolutionally efficient mechanism to control infection. Thus coagulation and platelets play a 
critical role in maintaining disease during process of immuno-hemostasis. 
In conclusion, platelets are key regulators of the immune system and immune function 
cannot be considered complete without considering platelet function. It may be hard for 
those who prescribe to the self non-self theory of immune function to swallow platelets as 
playing more than a bystander a role in immune function. If we look at platelets as derived 
from megakaryocytes, recent studies show that bacterial infection changes the profile of 
what transcripts platelets store and therefore produce after activation (Freishtat et al., 2009). 
Thus, maybe it is not the platelets that are in control, but feedback to and from the 
megakaryocyte. Alternatively, if we subscribe to the newly derived Danger theory of 
immune function (Matzinger, 2001; Matzinger, 2002), platelets as well as neutrophils fit the 
bill as perfect detectors of danger and mediators of immune response. We can easily see 
how over activation of platelets and neutrophils could signal danger and elicit a more 
robust immune response. Either way, platelets play an indispensible role in the immune 
system and the hemostatic response to immune challenges and we propose the beginning of 
a new scene in our studies, a scene where the platelet is the immunomodulator; in a scene 
called Immunohemostasis. 
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